From: Erratum: 2024;7(4):590-9 (DOI: 10.31662/jmaj.2024-0127)
| Items related to knowledge and skills (third to seventh terms) |
Mean achievement score (SD) | P value | Items related to knowledge and skills (eighth to ninth terms) |
Mean achievement score (SD) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-training | Post-training | Pre-training | Post-training | ||||||
| [Diagnosis and evaluation of food allergy] | |||||||||
| 1 | Diagnosis of immediate allergic response | 2.74 (0.64) | 3.70 (0.46) | <0.001* | 1 | Diagnosis of immediate allergic response | 2.81 (0.91) | 3.44 (0.73) | 0.010 |
| 2 | Explanation of the differences in diagnostic methods for FA | 2.36 (0.79) | 3.60 (0.54) | <0.001* | 2 | Explanation of the differences in diagnostic methods for FA | 2.69 (0.87) | 3.56 (0.63) | 0.002 |
| 3 | Interpretation of SPT results | 1.49 (0.80) | 3.38 (0.64) | <0.001* | 3 | Interpretation of SPT results | 2.13 (0.89) | 3.44 (0.51) | 0.001* |
| 4 | Diagnosis based on allergen components | 2.25 (0.86) | 3.44 (0.51) | <0.001* | |||||
| [Oral food challenge test] | |||||||||
| 4 | Explanation and giving informed consent for OFC | 2.39 (1.08) | 3.70 (0.51) | <0.001* | 5 | Explanation and giving informed consent for OFC | 2.38 (0.89) | 3.13 (0.89) | 0.031 |
| 5 | Prescription and treatment instructions for OFC | 2.09 (1.02) | 3.60 (0.54) | <0.001* | 6 | Prescription and treatment instructions for OFC | 2.00 (0.97) | 2.94 (0.77) | 0.003 |
| 6 | Supervision of preparation by the medical staff for OFC | 2.09 (1.04) | 3.66 (0.52) | <0.001* | 7 | Supervision of preparation by the medical staff for OFC | 2.38 (1.15) | 3.38 (0.72) | 0.005 |
| 7 | Preparation of the test food and medical devices for OFC | 1.66 (0.81) | 3.60 (0.54) | <0.001* | 8 | Preparation of test food and medical devices for OFC | 2.19 (1.05) | 3.25 (0.77) | 0.002 |
| 8 | Conducting OFC for a patient | 1.66 (0.81) | 3.53 (0.55) | <0.001* | 9 | Conducting OFC for a patient | 2.38 (1.09) | 3.50 (0.73) | 0.002 |
| 10 | Conducting double-blind food challenge tests | 1.81 (0.91) | 2.31 (0.87) | 0.015 | |||||
| [Dietary guidance] | |||||||||
| 9 | Listing notes in reintroducing foods for patients at low risk | 2.40 (0.88) | 3.49 (0.59) | <0.001* | 11 | Listing notes in reintroducing foods for patients at low risk | 2.44 (0.89) | 3.44 (0.63) | <0.001* |
| 10 | Listing notes for sensitized patients | 2.15 (0.81) | 3.45 (0.54) | <0.001* | 12 | Listing notes for sensitized patients | 2.38 (0.89) | 3.31 (0.60) | 0.002 |
| 11 | Guidance on partial introduction or reintroduction | 1.87 (0.80) | 3.12 (0.65) | <0.001* | 13 | Guidance on partial introduction or reintroduction | 2.31 (0.87) | 3.19 (0.91) | 0.002 |
| [Emergency treatment] | |||||||||
| 12 | Immediate allergic response and emergency action | 2.77 (0.79) | 3.83 (0.38) | <0.001* | 14 | Immediate allergic response and emergency action | 2.94 (0.77) | 3.56 (0.63) | 0.002 |
| 13 | Explanation of the efficacy and dosage of AAI | 2.68 (0.81) | 3.78 (0.42) | <0.001* | 15 | Explanation of the efficacy and dosage of AAI | 3.00 (0.73) | 3.69 (0.60) | 0.003 |
| 14 | Rules to the prescription of AAI | 2.32 (0.98) | 3.54 (0.66) | <0.001* | 16 | Rules about the prescription of AAI | 2.53 (0.99) | 3.31 (0.87) | 0.004 |
| 15 | Usage instructions for AAI | 2.68 (0.91) | 3.81 (0.45) | <0.001* | 17 | Usage instructions for AAI | 3.38 (0.72) | 3.69 (0.60) | 0.037 |
| [Management of atopic dermatitis] | |||||||||
| 16 | Description of the loss of skin barrier function, aggravating factors of AD | 2.51 (0.80) | 3.74 (0.44) | <0.001* | 18 | Diagnostic criteria of AD | 2.56 (0.81) | 3.56 (0.51) | 0.003 |
| 17 | Instructing techniques of skincare | 2.44 (0.69) | 3.79 (0.41) | <0.001* | 19 | Explanation of the loss of skin barrier function in AD | 2.44 (0.81) | 3.44 (0.51) | 0.002 |
| 18 | Explanation of the side effects of topical corticosteroids | 2.77 (0.60) | 3.81 (0.40) | <0.001* | 20 | Evaluation of the severity of AD | 2.25 (0.86) | 3.06 (0.57) | 0.007 |
| 19 | Avoiding side effects of topical corticosteroids | 2.34 (0.70) | 3.72 (0.45) | <0.001* | 21 | Instructing techniques of skincare | 2.63 (0.81) | 3.53 (0.64) | 0.004 |
| 20 | Idea of proactive treatment for AD | 2.47 (0.95) | 3.83 (0.38) | <0.001* | 22 | Avoiding side effects of topical corticosteroids | 2.50 (0.82) | 3.53 (0.52) | 0.002 |
| 23 | Idea of proactive treatment for AD | 2.63 (0.96) | 3.60 (0.51) | 0.005 | |||||
| 24 | Exacerbation factors of atopic dermatitis | 2.75 (0.68) | 3.53 (0.52) | 0.004 | |||||
| [Allergy prevention concept] | |||||||||
| 21 | Knowledge of the theory “dual-allergen exposure hypothesis” | 2.30 (0.93) | 3.77 (0.43) | <0.001* | 25 | Knowledge of the theory “dual-allergen exposure hypothesis” | 2.00 (0.89) | 3.33 (0.49) | <0.001* |
| [Management of asthma] | |||||||||
| 26 | Diagnostic criteria of asthma | 2.63 (0.72) | 3.40 (0.51) | 0.002 | |||||
| 27 | Evaluation of the severity and control status of asthma | 2.75 (0.68) | 3.47 (0.52) | 0.002 | |||||
| 28 | Exacerbation factors of asthma | 2.88 (0.62) | 3.60 (0.51) | 0.002 | |||||
| 29 | Evaluation of pulmonary function | 2.25 (1.00) | 3.33 (0.62) | 0.002 | |||||
| 30 | Evaluation of fractional exhaled nitric oxide (FeNO) | 2.06 (0.93) | 2.93 (0.70) | 0.002 | |||||
| 31 | Conducting airway sensitivity tests | 1.19 (0.40) | 2.07 (0.70) | 0.002 | |||||
| 32 | Long-term management of asthma | 2.63 (0.72) | 3.40 (0.51) | 0.006 | |||||
| 33 | Guidance on the lifestyle and household environment for preventing asthma exacerbation | 2.50 (0.89) | 3.40 (0.74) | 0.006 | |||||
| 34 | Inhalation device | 2.56 (1.03) | 3.40 (0.63) | 0.009 | |||||
| 35 | Action plans for acute asthma exacerbation | 2.94 (0.85) | 3.60 (0.51) | 0.005 | |||||
| [Allergic rhinitis] | |||||||||
| 36 | Sublingual immunotherapy | 2.06 (1.12) | 3.20 (0.68) | 0.005 | |||||
| [Patient education] | |||||||||
| 22 | Educational interventions for patients | 2.11 (0.68) | 3.43 (0.54) | <0.001* | |||||
